Seventure Reaffirms Microbiome Confidence With New €200m Fund

With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.

3d render illustration of human digestive system - front view
Exponential increase in microbiome potential

Seventure Partners is doubling down in the microbiome space with a new €200m fund Health for Life Capital II (HFL II). With 90% of limited partners from the first fund returning to back the new fund, the French VC has been able to announce a first closing north of €100m. Moreover, it has already started putting the new money to work participating in the $25m series B round completed by Axial Biotech Inc. and the Galecto Biotech AB €79m series C round.

“The microbiome field has gained such momentum since we raised HFL I four years ago that a few new LPs...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.